(Q30671597)

26 June 2017

1 reference

Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data (English)

1 reference

26 June 2017

1 reference

acute coronary syndrome

1 reference

inferred from title

author name string

Direct Thrombin Inhibitor Trialists' Collaborative Group

series ordinal

1

1 reference

26 June 2017

language of work or name

English

0 references

publication date

1 January 2002

1 reference

26 June 2017

1 reference

26 June 2017

volume

359

1 reference

26 June 2017

issue

9303

1 reference

26 June 2017

page(s)

294-302

1 reference

Are we mortgaging the medical profession?

26 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907495-0

7 January 2021

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907495-0

7 January 2021

Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907495-0

7 January 2021

An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907495-0

7 January 2021

Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907495-0

7 January 2021

Practical methodology of meta-analyses (overviews) using updated individual patient data. Cochrane Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907495-0

7 January 2021

Meta-analysis of the literature or of individual patient data: is there a difference?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907495-0

7 January 2021

Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907495-0

7 January 2021

Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907495-0

7 January 2021

Beta blockade during and after myocardial infarction: an overview of the randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907495-0

7 January 2021

Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907495-0

7 January 2021

Recombinant hirudin (lepirudin) for the improvement of thrombolysis with streptokinase in patients with acute myocardial infarction: results of the HIT-4 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907495-0

7 January 2021

Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907495-0

7 January 2021

A Comparison of Recombinant Hirudin with Heparin for the Treatment of Acute Coronary Syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907495-0

7 January 2021

Anticoagulant properties, clinical efficacy and safety of efegatran, a direct thrombin inhibitor, in patients with unstable angina

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907495-0

7 January 2021

Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation: a pilot study. Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907495-0

7 January 2021

A low molecular weight, selective thrombin inhibitor, inogatran, vs heparin, in unstable coronary artery disease in 1209 patients. A double-blind, randomized, dose-finding study. Thrombin inhibition in Myocardial Ischaemia (TRIM) study group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907495-0

7 January 2021

Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907495-0

7 January 2021

A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. Helvetica Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907495-0

7 January 2021

Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907495-0

7 January 2021

Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907495-0

7 January 2021

Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907495-0

7 January 2021

Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907495-0

7 January 2021

Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907495-0

7 January 2021

Biochemistry and biology of hirudin.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907495-0

7 January 2021

Recombinant hirudin in clinical practice: focus on lepirudin.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907495-0

7 January 2021

Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907495-0

7 January 2021

Direct thrombin inhibition and thrombolytic therapy: rationale for the Hirulog and Early Reperfusion/Occlusion (HERO-2) trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907495-0

7 January 2021

Evolution of improved antithrombotic and antiplatelet agents: genesis of the comparison of abciximab complications with hirulog [and back-up abciximab] events trial (CACHET)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907495-0

7 January 2021

50th Annual scientific sessions of the American college of cardiology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907495-0

7 January 2021

Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907495-0

7 January 2021

Antithrombotic agents in coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907495-0

7 January 2021

Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907495-0

7 January 2021

Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907495-0

7 January 2021

Are randomized clinical trials good for us (in the short term)? Evidence for a "trial effect".

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907495-0

7 January 2021

Implications of overviews of randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907495-0

7 January 2021

Summing up evidence: one answer is not always enough.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907495-0

7 January 2021

Why sources of heterogeneity in meta-analysis should be investigated

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907495-0

7 January 2021

Overcoming the limitations of current meta-analysis of randomised controlled trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907495-0

7 January 2021

Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907495-0

7 January 2021

10.1016/S0140-6736(02)07495-0

Identifiers

DOI

1 reference

26 June 2017

1 reference